#75 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Avicanna has sponsored a dose-finding clinical trial at the University of Calgary designed to optimize THC dosing in medical cannabis patients. This type of research addresses a critical gap in cannabis medicine, as standardized dosing protocols remain largely absent from clinical practice despite widespread medical use. The trial aims to establish evidence-based dosing guidelines that can improve therapeutic outcomes while minimizing adverse effects and optimizing the patient experience. For clinicians, the results could provide much-needed pharmacological data to inform individualized dosing recommendations for conditions commonly treated with cannabis. This research is particularly relevant given the variability in patient response to cannabis and the current reliance on empirical titration in clinical settings. Clinicians should monitor the publication of this trial’s findings, as validated dosing protocols could significantly enhance the scientific rigor and safety of cannabis-based medical practice.
“What we need from industry-sponsored research like this is honest dose-finding data, not just market validation, because my patients are still guessing at optimal dosing while we lack the rigorous pharmacokinetic studies that exist for every other medication I prescribe.”
💊 Industry sponsorship of clinical research on cannabis dosing presents both opportunities and important limitations for clinical practice. While dose-finding studies are genuinely needed to guide prescribing decisions in cannabis medicine, industry-sponsored trials warrant careful scrutiny regarding potential bias in study design, outcome selection, and dissemination of results. The heterogeneity of cannabis products, variable cannabinoid profiles, and individual patient factors affecting metabolism and response further complicate the translation of any single trial’s findings into generalizable dosing guidance. Healthcare providers should await publication of this trial’s full peer-reviewed results before incorporating findings into practice, remain attentive to funding sources when interpreting cannabis research, and continue individualizing dosing based on patient response given the current evidence gaps. Until robust, independent evidence accumulates across diverse patient populations, a cautious, titration-based approach with careful monitoring remains the prudent clinical strategy.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: